



# Figure S4


A




B



C



D



**Figure S4 BK-induced angiogenesis *in vitro* is reduced by B2R blockade.** (A) Representative pictures of microcarrier-HUVEC in 0.1% FBS (a), exposed to BK (1  $\mu$ M) (b), to fasitibant (1  $\mu$ M) (c), to fasitibant + BK (d). (B) Quantification of sprouting length ( $\mu$ m); Numbers represent mean  $\pm$  SEM of three experiments run in triplicate. \*\*\*  $p < 0.001$ , compared to untreated cells; ###  $p < 0.001$  to BK-treated cells. (C) Representative pictures of capillary structures (diameter) in microcarrier-HUVEC treated with BK (1  $\mu$ M, panel a) in presence/absence of fasitibant (1  $\mu$ M, panel b). (D) Quantification of sprouting diameter ( $\mu$ m); Numbers represent mean  $\pm$  SEM of three experiments run in triplicate. \*\*\*  $p < 0.001$ , compared to untreated cells; ###  $p < 0.001$  to BK-treated cells.